Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion

Core Viewpoint - Eli Lilly and Co. is expanding its domestic production capabilities by investing $3.5 billion in a new manufacturing facility in Pennsylvania, driven by the increasing sales of its obesity and diabetes treatments [1]. Group 1: Expansion Plans - The new plant will be located in Fogelsville, Pennsylvania, and is expected to produce injectable drugs and devices, including the weight-loss drug retatrutide, which is currently under study [3]. - This facility is part of a broader domestic expansion strategy that includes new plants in Texas, Virginia, and Alabama, along with an ongoing construction project in Indiana [2]. Group 2: Financial Performance - Eli Lilly reported a record third-quarter profit of $5.58 billion, with total revenue reaching $17.6 billion, reflecting an increase of over 50% compared to the same quarter last year [4]. - Sales from Zepbound and Mounjaro contributed significantly, accounting for $10 billion in sales during the third quarter [4].